Prurigo nodularis
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
References
Prurigo nodularis bụ ọnọdụ akpụkpọ ahụ na-adịte aka nke nwere ọtụtụ ọnya na nodules, nke a na-ahụkarị na akụkụ elu nke ogwe aka na ụkwụ. Ọkpụkpụ ndị a nwere ike ịdịgasị iche na agba site n'anụ ahụ ruo na pink ma na-ekpo ọkụ nke ukwuu. Ha nwere ike imetụta ndị nọ n'afọ ndụ ọ bụla ma na-ejikọta ya na ọnọdụ akpụkpọ anụ ndị ọzọ na-akpata itching na-adịghị ala ala, dị ka atopic dermatitis. Nhọrọ ọgwụgwọ gụnyere ọgwụ mgbochi siri ike, ọgwụ ndị na-emetụta usoro ahụ ji alụso ọrịa ọgụ, na ọgwụ ndị na-elekwasị anya n'usoro ahụ ụjọ. Ijikwa nodularis prurigo na-agụnyekarị ọgwụgwọ ogologo oge.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Ọgwụgwọ na-agụnyekarị iji ude ma ọ bụ injections nke steroid na mpaghara ahụ metụtara. N'ọnọdụ siri ike ma ọ bụ isi ike, ọgwụgwọ dị ka ọgwụgwọ ọkụ ma ọ bụ ọgwụ na-egbochi usoro ahụ ji alụso ọrịa ọgụ nwere ike ịdị mkpa. Thalidomide na lenalidomide bụ nhọrọ maka ikpe siri ike, mana ha nwere ike inwe mmetụta dị njọ. Ọgwụgwọ ọhụrụ (opioid receptor antagonists, neurokinin-1 receptor antagonists) na-egosi nkwa n'ịgwọ prurigo nodularis nwere mmetụta dị ole na ole ma e jiri ya tụnyere thalidomide ma ọ bụ lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Chronic prurigo bụ ọnọdụ akpụkpọ ahụ nke e ji itching na-adịte aka (na-adịru ihe karịrị izu isii) , ọnya akpụkpọ ahụ metụtara ọkọ, na akụkọ ihe mere eme nke ịchacha mgbe niile. Ọ na-agụnye neuroinflammation na fibrosis na akpụkpọ.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis bụ nsogbu akpụkpọ ahụ na-adịte aka nke nodules na-egbuke egbuke mara. Anyị amaghị kpọmkwem ihe na-akpata ya, ma ọ dị ka ihe ndị na-alụso ọrịa ọgụ na akwara na-ekere òkè n'ọkpụkpụ ichichi. Ugbu a, ọ nweghị ọgwụgwọ ọ bụla nke US FDA kwadoro kpọmkwem maka prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Ọgwụgwọ ― OTC Ọgwụ
Iji ncha na-asa ebe mmerụ ahụ adịghị enyere aka ma ọ nwere ike ime ka ọ ka njọ. OTC steroid ointments nwere ike inye aka belata mgbaàmà ahụ, mana ọ na-adịkarị mkpa ka etinye ya ruo ọtụtụ izu iji meziwanye. Ịga n'ihu na-aṅụ ọgwụ antihistamines na-enyekwa aka belata itching.
#OTC steroid ointment
#OTC antihistamine
○ Ọgwụgwọ
#Intralesional triamcinolone injection